# US 2023/0069711 A1 · Nitric oxide-releasing device

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0069711 A1
- Document ID: US20230069711A1
- Status: Published application
- Kind: A1
- Application number: 17/823,298
- Filed: 2022-08-30
- Published: 2023-03-02
- Earliest claimed: 2021-08-30
- Assignees: Albert Einstein College of Medicine
- Applicants: Albert Einstein College of Medicine
- Inventors: Joel M. Friedman
- Web page: https://patentgrep.com/patent/US20230069711A1

## CPC

- A61K 9/0043: {Nose}
- A61M 31/00: Devices for introducing or retaining media, e.g. remedies, in cavities of the body (A61M25/00 takes precedence {; introducing or retaining ophthalmic products into the ocular cavities A61F9/0008})
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 33/30: Zinc; Compounds thereof
- A61K 33/34: Copper; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/46: Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- A61M 35/30: {Gas therapy for therapeutic treatment of the skin}
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 9/0046: {Ear}
- A61M 2202/0275: Nitric oxide [NO]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

A device for generating nitric oxide is disclosed. The device is configured for applying to either a body cavity or a surface of a subject in need thereof. Also disclosed is a method for the treatment of diseases or conditions with the device.

## Claims

### Claim 1

A method of treating a disease or condition in a subject, comprising:
(a) placing a device in a body cavity or a surface of the subject in need thereof,
wherein the device comprises:
a nitrite source;
a reservoir for loading the nitrite source and configured for being applied to the body cavity or the surface of the subject;
(b) contacting the nitrite source with a proton source to generates a therapeutically effective amount of nitric oxide (NO).

### Claim 2 (depends on 1)

The method of claim 1, wherein the nitrite source and the proton source are separately stored in the device prior to the device being applied to the body cavity.

### Claim 3 (depends on 1)

The method of claim 1, wherein the proton source is physically separate from the device.

### Claim 4 (depends on 1)

The method of claim 1, wherein the nitrite source comprises an alkali metal nitrite, an alkaline earth metal nitrite, a transition metal nitrite, an ammonium nitrite or any combination thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the nitrite source comprises nitrite loaded nanoparticles.

### Claim 6 (depends on 1)

The method of claim 1, wherein the proton source is water.

### Claim 7 (depends on 1)

The method of claim 1, wherein one or both of the nitrite source and the proton source are independently admixed with a gelling agent and/or a viscosity adjuster prior to the contact with the proton source.

### Claim 8 (depends on 7)

The method of claim 7, wherein the gelling agent comprising a material selected from the group consisting of honey, xanthan gum, guar gum, carrageenan gum, locust bean gum, sodium alginate, agar-agar, gelatin, modified starches, cellulose, crosslinked polyacrylic acids, and alkyl-substituted celluloses, wherein the gelling agent optionally further comprises a dilutor for adjusting the viscosity of the gelling agent.

### Claim 9 (depends on 7)

The method of claim 7, wherein the gelling agent comprises honey.

### Claim 10 (depends on 7)

The method of claim 7, wherein the nitrite source and/or the proton source are separately stored in the device from the gelling agent and/or the viscosity adjuster prior to being admixed with the gelling agent and/or the viscosity, and the method comprising admixing the nitrite source and/or the proton source independently with the gelling agent and/or the viscosity adjuster.

### Claim 11 (depends on 7)

The method of claim 7, wherein one or both of the nitrite source and the proton source are independently admixed with PEG prior to the contact between the nitrite source and the proton source.

### Claim 12 (depends on 7)

The method of claim 7, wherein the gelling agent and/or the viscosity adjuster and their respective amounts are selected to provide an extended release of the therapeutically effective amount of the NO over a period of at least 24 hours.

### Claim 13 (depends on 1)

The method of claim 1, wherein the reservoir is further loaded with a thiol source.

### Claim 14 (depends on 13)

The method of claim 13, wherein the source of thiol group is thiol-containing molecules.

### Claim 15 (depends on 13)

The method of claim 13, wherein the thiol source is thiol-containing nanoparticles, which either have the having thiol groups covalently thereto or have thiol-containing molecules loaded in the nanoparticles.

### Claim 16 (depends on 1)

The method of claim 1, further comprising a source of S-nitrosothiol (SNO) group.

### Claim 17 (depends on 1)

The method of claim 1, wherein the nitrite source comprises an immediate release portion and an extended release portion.

### Claim 18 (depends on 1)

The method of claim 1, wherein the disease or condition is viral or bacterial infection, inflammation, neuropathic pain, sinusitis, cystic fibrosis, bronchiectasis, surgical or trauma induced wounds, vaginal deterioration, and sexual dysfunction.

### Claim 19 (depends on 1)

The method of claim 1, wherein the body cavity is nose, nasal sinuses, ears, rectum, vagina, mucosa surface in the mouth, or an open wound.

### Claim 20 (depends on 1)

The method of claim 1, wherein the device is inserted into the nostril of the subject to treat chronic sinusitis, neuropathic pain, cystic fibrosis or bronchiectasis.

### Claim 21 (depends on 1)

The method of claim 1, wherein the device is inserted into the nostril of the subject to the ear of the subject to treat inner or outer ear infection.

### Claim 22 (depends on 1)

The method of claim 1, wherein the device is applied to the subject prophylactically.

### Claim 23 (depends on 1)

The method of claim 1, wherein the reservoir is a sponge or a patch.
